SeekingAlpha · Sep 14, 2026
IN
NASDAQ · INBX
Inhibrx Biosciences, Inc.
Healthcare · Biotechnology
$105.61
Down-$2.65 (-2.51%)
Updated Sep 16, 2026, 4:46 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.2B
- P/E ratio
- -8.2
- Dividend yield
- 0.00%
- 52-week range
- $57.30 – $155.29
- Volume
- 251.6K
- Avg. volume
- 370.47K
Price performance
INBX price history
1M range · 20 trading sessions · Daily adjusted prices
INBX closed at $105.61 after 20 trading sessions, up 11.61% for the selected period.
- Last close
- $105.61
- Period change
- +11.61%
- Period low
- $94.62
- Period high
- $126.70
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $109.44 | $109.44 | $104.845 | $105.61 | 251.6K |
| Sep 14, 2026 | $109.10 | $111.44 | $104.90 | $110.47 | 239.99K |
| Sep 11, 2026 | $113.00 | $115.11 | $108.93 | $109.27 | 211.02K |
| Sep 10, 2026 | $109.23 | $113.949 | $107.22 | $111.42 | 313.89K |
| Sep 9, 2026 | $117.38 | $128.54 | $112.03 | $112.86 | 677.83K |
| Sep 8, 2026 | $117.22 | $120.1825 | $94.0001 | $114.34 | 1.68M |
| Sep 4, 2026 | $121.04 | $124.19 | $120.48 | $121.17 | 196.51K |
| Sep 3, 2026 | $125.20 | $126.00 | $120.17 | $122.26 | 151.71K |
| Sep 2, 2026 | $125.61 | $127.7525 | $121.25 | $124.97 | 189.89K |
| Sep 1, 2026 | $124.98 | $129.88 | $120.62 | $124.66 | 275.91K |
| Aug 31, 2026 | $123.39 | $128.87 | $121.59 | $126.70 | 388.98K |
| Aug 28, 2026 | $123.80 | $126.04 | $119.38 | $123.41 | 241.48K |
| Aug 27, 2026 | $124.27 | $127.34 | $122.355 | $123.93 | 310.88K |
| Aug 26, 2026 | $123.00 | $131.01 | $119.435 | $125.34 | 302.86K |
| Aug 25, 2026 | $105.50 | $126.50 | $104.71 | $122.72 | 510.62K |
| Aug 24, 2026 | $105.00 | $105.14 | $94.20 | $104.94 | 373.62K |
| Aug 21, 2026 | $100.76 | $105.65 | $99.05 | $103.63 | 220.74K |
| Aug 20, 2026 | $98.65 | $102.4999 | $96.565 | $99.15 | 351.49K |
| Aug 19, 2026 | $96.01 | $102.25 | $95.27 | $101.48 | 310.66K |
| Aug 18, 2026 | $89.83 | $94.89 | $89.00 | $94.62 | 311.23K |
Latest INBX news
The latest Smart Investors Daily articles mentioning INBX.
Stock researchCompany · Overview
INBX research
Overview
Company profile and research snapshot.
Company profile
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $12.24
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | Stifel | Buy | — |
| Aug 22, 2025 | JMP Securities | Market Perform | — |
| May 15, 2025 | JMP Securities | Market Perform | — |
| Mar 18, 2025 | Citizens Capital Markets | Market Perform | — |
News briefing
Generated Sep 16, 2026, 5:11 PM
Why Is INBX Down Today?
Inhibrx Biosciences shares declined 2.39% despite positive clinical and regulatory developments in its pipeline. The selloff appears disconnected from recent news, suggesting profit-taking or broader market headwinds may be driving the price action rather than company-specific negative catalysts.
Bottom line: INBX's decline appears disconnected from strengthening clinical developments and upcoming regulatory milestones, potentially presenting a buying opportunity for investors with conviction in the pipeline. Key risks include regulatory disappointment and clinical execution, but the 'Strong Buy' thesis hinges on upcoming Ozekibart decision and expanding pipeline validation from the INBRX-106 win.
SeekingAlpha · Sep 9, 2026
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx (INBX) updates: ozekibart & INBRX-106 show strong rare cancer and immuno-oncology data; FDA BLA due Apr 2027.
Yahoo · Sep 8, 2026
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
Inhibrx Biosciences (NASDAQ:INBX) shares gained 6% on Tuesday after the biotechnology company reported encouraging Phase 2 results for INBRX-106 in combination with pembrolizumab in patients with head and neck cancer. Data from the HexAgon study showed a confirmed objective response rate of 48.
Yahoo · Sep 8, 2026
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the primary endpoint results from the randomized and controlled Phase 2 portion of the HexAgon study, which is evaluating the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, in combination with pembrolizumab (the combination arm) versus pembrolizumab monotherapy (the control
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
